Amgen Inc. logo

Amgen Inc. (AMGN)

Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS)
$
432. 49
-1.54
-0.3548%
$
223.91B Market Cap
19.61 P/E Ratio
0.07% Div Yield
2.56M Volume
18.58 Eps
$ 434.03
Previous Close
Add Transaction
Day Range
431.43 438.82
Year Range
288 447.03
Want to track AMGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case

Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.

Reuters | 1 year ago
Why Amgen (AMGN) Dipped More Than Broader Market Today

Why Amgen (AMGN) Dipped More Than Broader Market Today

Amgen (AMGN) reachead $316.74 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.

Zacks | 1 year ago
Is Amgen Stock a Buy?

Is Amgen Stock a Buy?

This biotech leader could be poised to rally higher.

Fool | 1 year ago
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts

Amgen (AMGN) Rises As Market Takes a Dip: Key Facts

Amgen (AMGN) closed at $325.09 in the latest trading session, marking a +0.14% move from the prior day.

Zacks | 2 years ago
Calls of the Day: Amgen, Albemarle, Tesla, Broadcom and Caterpillar

Calls of the Day: Amgen, Albemarle, Tesla, Broadcom and Caterpillar

The Investment Committee discuss the latest Calls Of The Day.

Youtube | 2 years ago
Amgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.

Amgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.

The pharma company has a lot riding on its experimental obesity drug MariTide.

Barrons | 2 years ago
Amgen's stock falls as analyst warns that hype around obesity drug is baked in

Amgen's stock falls as analyst warns that hype around obesity drug is baked in

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech's drug pipeline.

Marketwatch | 2 years ago
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 2 years ago
2 Top Dividend Stocks to Buy Hand Over Fist Right Now

2 Top Dividend Stocks to Buy Hand Over Fist Right Now

Income stocks can be wise additions to your portfolio in any market environment.

Fool | 2 years ago
2 Biotech Stocks to Buy Hand Over Fist in October

2 Biotech Stocks to Buy Hand Over Fist in October

These longtime leading biotech stocks still have plenty of upside ahead.

Fool | 2 years ago
The Art of Valuation: Discovering Amgen Inc's Intrinsic Value

The Art of Valuation: Discovering Amgen Inc's Intrinsic Value

In this article, we will take a look into Amgen Inc's (AMGN, Financial) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow as in the traditional DCF model, the GuruFocus DCF calculator uses EPS without NRI as the default for the DCF model based on research that shows that historically stock prices have been more correlated with earnings than free cash flow.

Gurufocus | 2 years ago
Loading...
Load More